Across TCGA pan-cancer cohorts, SMG5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMG5 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SMG5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SMG5 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

STAD, HNSC, and COAD are the cancer types where SMG5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	1.000	0.373	.018	12	view →
HNSC	DFS	Median	IV	0.122	0.670	.008	9	view →
COAD	OS	Median	III,IV	0.133	0.696	.019	6	view →
SKCM	DFS	Median	III,IV	0.084	0.655	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SMG5 tumor-vs-normal RNA expression · all SMG5 data types